Previous 10 | Next 10 |
Reports 78% increase in revenue and 92% increase in gross profit for fiscal 2019 Generated over $3.1 million in sales through POCare platform Rapidly expanding POCare platform through new collaborations GERMANTOWN, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NA...
GERMANTOWN, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopk...
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59% 5-year CAGR of Masthercell under Orgenesis’ leadership Reports rapid progress in roll-out of point-of-care (POCare) platform to capitalize on industry demand for patient cell processing and tre...
Thinly traded nanoc cap Orgenesis (NASDAQ: ORGS ) jumps 35% premarket on modest volume in reaction to its agreement to sell subsidiary MaSTherCell Global, a contract development and manufacturing organization, to Catalent (NYSE: CTLT ) for ~$127M. More news on: Orgenesis Inc....
GERMANTOWN, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Global, Inc., a contract development manufacturing organization...
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract developmen...
Orgenesis (NASDAQ: ORGS ) has entered into a definitive securities purchase agreement with certain institutional investors, for the sale of 2.2M common shares in a private placement at $4.20 per share and warrants to purchase up to 1M common shares at an exercise price of $5.50 per share. ...
GERMANTOWN, Md., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH ...
GERMANTOWN, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Gl...
GERMANTOWN, Md., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services, as well as localized point-of-care development and processing centers through its subsidiary ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 2.7% to $127.255 on volume of 88,797,787 shares Ascent Solar Technologies Inc (ASTI) rose 9.6% to $0.1183 on volume of 88,651,038 shares Crown Electrokinetics Corp. (CRKN) fell 19.0% to $0.040499 on volu...